Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash & Equivalents (2020 - 2025)

Tango Therapeutics has reported Cash & Equivalents over the past 6 years, most recently at $112.3 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $112.3 million for Q4 2025, up 61.48% from a year ago — trailing twelve months through Dec 2025 was $112.3 million (up 61.48% YoY), and the annual figure for FY2025 was $112.3 million, up 61.48%.
  • Cash & Equivalents for Q4 2025 was $112.3 million at Tango Therapeutics, up from $58.3 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for TNGX hit a ceiling of $205.0 million in Q3 2021 and a floor of $39.3 million in Q2 2025.
  • Median Cash & Equivalents over the past 5 years was $63.5 million (2021), compared with a mean of $79.2 million.
  • Biggest five-year swings in Cash & Equivalents: surged 203565.03% in 2021 and later crashed 58.65% in 2022.
  • Tango Therapeutics' Cash & Equivalents stood at $145.0 million in 2021, then tumbled by 58.65% to $60.0 million in 2022, then rose by 10.7% to $66.4 million in 2023, then increased by 4.74% to $69.5 million in 2024, then surged by 61.48% to $112.3 million in 2025.
  • The last three reported values for Cash & Equivalents were $112.3 million (Q4 2025), $58.3 million (Q3 2025), and $39.3 million (Q2 2025) per Business Quant data.